What are the lessons learned from the many Danish biotech companies that have been forced to call it quits, and what have the ups and downs of the noughts meant for the investor environment in Denmark? Medwatch is looking for the answers in a new miniseries.
Novo A/S wants to continue the good development in newly purchased company Sonion, which matches the company’s strategy perfectly, says CEO Eivind Kolding. The acquisition is, however, not to be seen as a sign that the holding company is moving away from the biotech sector, he says.
Morgan Stanley has included the GN Store Nord share on its list of ‘Best Ideas’ on a global scale. The major bank sees room for additional increases at a time when most other banks are less bullish about the share.
From 2000 to 2004 around 70 biotech companies were founded in Denmark. But how many are still running? And have the companies been successful or not, collectively speaking? Medwatch attempts to provide the answer in a new miniseries.
An analyst from Nordic Bioinvestor sees it as a positive thing for Bavarian Nordic, should a major US rival buckle under recent financial pressure. The analyst is bullish on the share, not least due to the company’s infectious diseases division.
Danish scientist have discovered and mapped previously unknown micro organisms and bacteria viruses. The discovery could replace the use of antibiotics and improve treatment and prevention of diseases such as type 2 diabetes, asthma and intestinal diseases.
US-based biotech company Celladon, in which Lundbeckfond Ventures is a major shareholder, is targeting a larger number of indications with its most promising candidate drug and is launching new studies.
Topotarget is almost at the finish line and it is with mixed emotions that CEO Anders Vadsholt takes stock of the situation. He is leaving his post due to the upcoming merger with BioAlliance Pharma, but what is to become of the rest of the staff?
Danish biotech Forward Pharma, in which major investor Florian Schönharting is Chairman of the board, has received a binding commitment for a massive capital injection. But what will the money be used on?
An employee’s level of commitment can be affected by circumstances in the family, such as disease – and the company should be sensitive to that. But if people are down-right uncommitted, the corporate culture is so strong that it will gradually expel them. Lars Rebien, at the peak of his career, spoke to Medwatch about the unique Novo spirit, about failing politicians, and about growing softer.
Gitte Pedersen’s career began in Novo Nordisk and the Danish drug giant led her to the US, where she is now CEO and co-founder of a diagnostics company in Manhattan – a career that is partly formed by a past peopled by engineers and women’s rights activists.